| Name | Abemaciclib methanesulfonate |
| Description | Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM). |
| Cell Research | LY2835219 is dissolved in DMSO to a 10 mM concentration.? Cells are seeded in a 96-well plate, allowed to adhere overnight, and treated with DMSO control (0.1% v/v) or the indicated compounds for 72 h. Cell viability and proliferation are determined using a Cell Counting Kit according to the manufacturer's instructions. The interaction between LY2835219 and mTOR inhibitor is determined using CompuSyn. Combination index (CI) values of 1 indicates and additive drug interaction, whereas a CI of < 1 is synergistic and a CI of > 1 is antagonistic. |
| Kinase Assay | Cells (5 × 103) are plated in 96 well plates. Cells are treated the next day for 24 to 48 hours and then assessed for caspase-3 activity by Caspase-Glo-3/7 Assay, as per manufacturer's instructions and a luminescence plate reader. |
| In vitro | In subcutaneous and intracranial glioma models (U87 mg), MsOH treatment results in LY2835219 inhibiting tumor growth in a dose-dependent manner. |
| In vivo | In retinoblastoma, LY2835219 inhibits cancer cell growth by specifically targeting and inhibiting CDK4 and CDK6, leading to cell cycle arrest at the G1 phase and suppression of DNA synthesis. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 45 mg/mL (74.7 mM)
DMSO : 6.03 mg/mL (10 mM), Sonication is recommended.
Ethanol : 23 mg/mL (38.2 mM)
|
| Keywords | inhibit | Inhibitor | Cyclin dependent kinase | LY 2835219 | Abemaciclib | CDK | LY2835219 Mesylate | LY-2835219 | Abemaciclib methanesulfonate | LY-2835219 Mesylate | methanesulfonate | LY 2835219 Mesylate | abemaciclib Mesylate |
| Inhibitors Related | Ribociclib | Ro-3306 | GSK 3 Inhibitor IX | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Abemaciclib | Dinaciclib |
| Related Compound Libraries | Kinase Inhibitor Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
